CytoDyn Inc. (CYDY)
OTCMKTS · Delayed Price · Currency is USD
0.3130
+0.0030 (0.97%)
Apr 30, 2026, 1:45 PM EST
CytoDyn Employees
CytoDyn had 13 employees as of May 31, 2025. The number of employees increased by 4 or 44.44% compared to the previous year.
Employees
13
Change (1Y)
4
Growth (1Y)
44.44%
Revenue / Employee
n/a
Profits / Employee
-$3,098,154
Market Cap
423.47M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| May 31, 2025 | 13 | 4 | 44.44% |
| May 31, 2024 | 9 | -3 | -25.00% |
| May 31, 2023 | 12 | -11 | -47.83% |
| May 31, 2022 | 23 | -1 | -4.17% |
| May 31, 2021 | 24 | 5 | 26.32% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Northwest Biotherapeutics | 105 |
| Silence Therapeutics | 88 |
| Vaxart | 65 |
| Nuo Therapeutics | 10 |
| Cell Source | 1 |
CytoDyn News
- 3 days ago - CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer - GlobeNewsWire
- 7 days ago - CytoDyn to Host Investor Webcast - GlobeNewsWire
- 8 days ago - CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 - GlobeNewsWire
- 8 days ago - CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study - GlobeNewsWire
- 10 days ago - CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 - GlobeNewsWire
- 16 days ago - CytoDyn to Present at the AACR Annual Meeting 2026 - GlobeNewsWire
- 5 weeks ago - CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer - GlobeNewsWire
- 2 months ago - CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab - GlobeNewsWire